The production of H2O2, which is essential to thyroid hormone synthesis, involves two NADPH oxidases: dual oxidases 1 and 2 (DuOx1 and DuOx2). A functional study with human DuOx genes and their 5′-flanking regions showed that DuOx1 and -2 promoters are different from thyroid-specific gene promoters. Furthermore, their transcriptional activities are not restricted to thyroid cells. While regulation of Tg (thyroglobulin) and TPO (thyroperoxidase) expression have been extensively studied, DuOx2 promoter regulation by hormones and transcriptional factors need to be more explored. Herein we investigated the role of TSH, insulin and insulin-like growth factor 1 (IGF-1), as well as the cAMP effect on DuOx2 promoter (ptx41) activity in transfected rat thyroid cell lines (PCCL3). We also assessed DuOx2 promoter activity in the presence of transcriptional factors crucial to thyroid development such as TTF-1 (thyroid transcription factor 1), PAX8, CREB, DREAM, Nkx2.5 and the coactivator TAZ in HeLa and HEK 293T-transfected cells. Our results show that TSH and forskolin, which increase cAMP in thyroid cells, stimulated DuOx2 promoter activity. IGF-1 led to pronounced stimulation, while insulin induction was not statistically different from DuOx2 promoter basal activity. All transcriptional factors selected for this work and coactivator TAZ, except DREAM, stimulated DuOx2 promoter activity. Moreover, Nkx2.5 and TAZ synergistically increased DuOx2 promoter activity. In conclusion, we show that DuOx2 expression is regulated by hormones and transcription factors involved in thyroid organogenesis and carcinogenesis, reinforcing the importance of the control of H2O2 generation in the thyroid.

Keywords:
DuOx2 promoter, Thyroid, Nkx2.5, TAZ
1.
De Deken X, Dantong W, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE, Miot F: Cloning of two human cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 2000;275:23227-23233.
2.
Milenkovic M, De Deken X, Jin L, De Felice M, Di Lauro R, Dumont JE, Corvilain B, Miot F: DuOx expression and related H2O2 measurement in mouse thyroid: onset in embryonic development and regulation by TSH in adult. J Endocrinol 2007;192:615-626.
3.
Pachucki J, Wang D, Christophe D, Miot F: Structural and functional characterization of the two human ThOX/Duox genes and their 5´-flanking regions. Mol Cell Endocrinol 2004;214:53-62.
4.
Dupuy C, Dème D, Kaniewski J, Pommier J, Virion A: Ca2+ regulation of thyroid NADPH-dependent H2O2 generation. FEBS Lett 1988;233:74-78.
5.
Carvalho DP, Dupuy C, Gorin Y, Legue O, Pommier J, Haye B, Virion A: The Ca2+ and reduced nicotidamide adenine dinucleotide phosphate-dependent H2O2 generation system is induced by thyrotropin in porcine thyroid cells. Endocrinology 1996;137:1007-1012.
6.
Cardoso LC, Martins DCL, Figueiredo MDL, Domingos MG, Vaisman M, Carvalho DP: Ca2+/nicotinamide adenine dinucleotide phosphate-dependent H2O2 generation is inhibited by iodide in human thyroids. J Clin Endocrinol Metab 2001;86:4339-4343.
7.
Cardoso LC, Martins DCL, Campos DVB, Santos LM, Costa VMC, Rosenthal D, Vaisman M, Violante AHD, Carvalho DP: Effect of iodide or iopanoic acid on thyroid Ca2+/NADPH-dependent H2O2 generating activity and thyroperoxidase in toxic diffuse goiters. Eur J Endocrinol 2002;147:293-298.
8.
Morand S, Chaaraoui M, Kaniewski J, Dème D, Ohayon R, Noel-Hudson MS, Virion A, Dos Santos OF, Dupuy C: Identification of a truncated dual oxidase 2 (DUOX2) messenger ribonucleic acid (mRNA) in two rat thyroid cell lines. Insulin and forskolin regulation of DUOX2 mRNA levels in FRTL-5 cells and porcine thyrocytes. Endocrinology 2003;144:567-574.
9.
Figueiredo MDL, Cardoso LC, Ferreira ACF, Campos DVB, Domingos MG, Corbo R, Nasciutti LE, Vaisman M, Carvalho DP: Goiter and hyporthyroidism in two siblings due to impaired Ca2+/NADPH-dependent H2O2 generating activity. J Clin Endocrinol Metab 2001;86:4843-4848.
10.
Moreno JC, Bikker H, Kempers MJ, van Trostsenburg AS, Bass F, de Vijlder JJ, Vulsma T, Ris-Stalpers C: Inactivating mutations in the gene for thyroid oxidase 2 (Thox 2) and congenital hypothyroidism. N Engl J Med 2002;347:95-102.
11.
Moreno JC, Visser TJ: New phenotypes in thyroid dyshormonogenesis: hypothyroidism due to DUOX2 mutations. Endocr Dev 2007;10:99-117.
12.
Deleu S, Pirson I, Coulonval K, Drouin A, Taton M, Clermont F, Roger PP, Nakamura T, Dumont JE, Maenhaut C: IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. Mol Cell Endocrinol 1999;149:41-51.
13.
Dumont JE, Lamy F, Roger P, Maenhaut C: Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 2002;72:667-697.
14.
Pasca Di Magliano M, Di Lauro R, Zannini M: Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 2000;97:13144-13149.
15.
Espinoza CR, Schmitt TL, Loos U: Thyroid transcription factor 1 and Pax8 synergistically activate the promoter of the human thyroglobulin gene. J Mol Endocrinol 2001;27:59-67.
16.
Di Palma T, Nitsch R, Mascia A, Nitsch L, Di Lauro R, Zannini M: The paired domain-containing factor Pax8 and the homeodomain-containing factor TTF-1 directly interact and synergistically activate transcription. J Biol Chem 2003;278:3395-3402.
17.
Damante G, Tell G, Di Lauro R: A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acid Res Mol Biol 2001;66:307-356.
18.
de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, Fusco A, Zannini M: TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer 2011;7:926-933.
19.
Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, et al: TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000;19:6778-6791.
20.
Chen CY, Schwartz RJ: Identification of novel DNA binding targets and regulatory domains of a murine tinman homeodomain factor, Nkx-2.5. J Biol Chem 1995;270:15628-15633.
21.
Dentice M, Cordeddu V, Rosica A, Ferrara AM, Santarpia L, Salvatore D, Chiovato L, et al: Missense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesis. J Clin Endocrinol Metab 2006:91:1428-1433.
22.
Carrion AM, Link WA, Ledo F, Mellstrom B, Naranjo JR: DREAM is a Ca2+-regulated transcriptional repressor. Nature 1999;398:80-84.
23.
Rivas M, Mellström B, Torres B, Cali G, Ferrara AM, Terracciano D, Zannini M, Morreale de Escobar G, Naranjo JR: The DREAM protein is associated with thyroid enlargement and nodular development. Mol Endocrinol 2009;23:862-870.
24.
Rivas M, Mellström B, Naranjo JR, Santisteban P: Transcriptional repressor DREAM interacts with thyroid transcription factor-1 and regulates thyroglobulin gene expression. J Biol Chem 2004;279:33114-33122.
25.
Pohlenz J, Dumitrescu A, Zundel D, Martiné U, Schönberger W, Koo E, Weiss RE, et al: Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. J Clin Invest 2002;109:469-73.
26.
Vilain C, Rydlewski C, Duprez L, Heinrichs C, Abramowicz M, Malvaux P, Renneboog B, et al: Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-function mutation of PAX8. J Clin Endocrinol Metab 2001;86:234-238.
27.
Kasahara H, Usheva A, Ueyama T, Aoki H, Horikoshi N, Izumo S: Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein. J Biol Chem 2001;276:4570-4580.
28.
Chen C, Okayama H: Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 1988;6:632-639.
29.
Di Palma T, D'Andrea B, Liguorib GL, Liguorob A, De Cristofaroa T, Del Pretea D, Pappalardoa A, Masciaa A, Zannini M: TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp Cell Res 2009;315:162-175.
30.
Ledo F, Kremer L, Mellström B, Naranjo JR: Ca2+-dependent block of CREB-CBP transcription by repressor DREAM. EMBO J 2002;21:4583-4592.
31.
Christophe-Hobertus C, Christophe D: Human thyroid oxidases genes promoter activity in thyrocytes does not appear to be functionally dependent on thyroid transcription factor-1 or Pax8. Mol Cell Endocrinol 2007;264:157-163.
32.
Dentice M, Luongo C, Elefante A, Romino R, Ambrosio R, Vitale M, Rossi G, Fenzi G, Salvatore D: Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells. Mol Cell Biol 2004;24:7863-7877.
33.
Rigutto S, Hoste C, Dumont JE, Corvilain B, Miot F, De Deken X: DuOx1 is the main source of hydrogen peroxide in the rat thyroid cell line PCCl3. Exp Cell Res 2007;313:3892-3901.
34.
Santisteban P, Acebrón A, Polycarpou-Schwarz M, Di Lauro R: Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol 1992;6:1310-1317.
35.
Aza-Blanc P, Di Lauro R, Santisteban P: Identification of a cis-regulatory element and a thyroid-specific nuclear factor mediating the hormonal regulation of rat thyroid peroxidase promoter activity. Mol Endocrinol 1993;7:1297-1306.
36.
Krohn K, Maier J, Paschke R: Mechanisms of disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat Clin Pract Endocrinol Metab 2007;3:713-720.
37.
De Felice M, Di Lauro R: Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev 2004;25:722-746.
38.
D'Andrea B, Iacone R, Di Palma T, Nitsch R, Baratta MG, Nitsch L, Di Lauro R, Zannini M: Functional inactivation of the transcription factor Pax8 through oligomerization chain reaction. Mol Endocrinol 2006;20:1810-1824.
39.
Fernández LP, López-Márquez A, Martínez AM, Gómez-López G, Santisteban P: New insights into FoxE1 functions: identification of direct FoxE1 targets in thyroid cells. PLoS One 2013;8:e62849.
40.
Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP: Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2011;22:631-656.
© 2015 European Thyroid Association Published by S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.